Section Arrow
Quote
IOVA.NASDAQ
- Iovance Biotherapeutics
Quotes are at least 15-min delayed:2026/03/29 19:30 EDT
Regular Hours
Last
 3.51
-0.18 (-4.88%)
Day High 
3.715 
Prev. Close
3.69 
1-M High
5.63 
Volume 
8.50M 
Bid
3.5
Ask
3.55
Day Low
3.51 
Open
3.66 
1-M Low
3.43 
Market Cap 
1.46B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 3.79 
20-SMA 4.14 
50-SMA 3.29 
52-W High 5.63 
52-W Low 1.6385 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.09/-0.28
Enterprise Value
1.51B
Balance Sheet
Book Value Per Share
1.70
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
263.50M
Operating Revenue Per Share
0.00
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ITRMIterum Therapeutics plc0.0356-0.1404-79.77%-- 
ARTLArtelo Biosciences Inc10.54+7.35+230.41%-- 
ONCOOnconetix Inc1.94-1.28-39.75%0PE
RCKTRocket Pharmaceuticals3.77-0.92-19.62%-- 
ADMAADMA Biologics9.25+0.96+11.58%13.87PE
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.